Hypolipidemické účinky silymarinu nejsou zprostředkovány peroxisomovými proliferátory-aktivovaným receptorem alfa
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F07%3A00004221" target="_blank" >RIV/61989592:15110/07:00004221 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha
Popis výsledku v původním jazyce
Silymarin is widely used in supportive therapy of liver diseases. It has been shown lately that silymarin has beneficial effects on some risk factors of atherosclerosis owing to its hypolipidemic properties. PPAR? plays a key role in lipid metabolism andhomeostasis as its target genes are involved in catabolism of fatty acids by ?-oxidation (e.g. acyl-CoA oxidase) and by ?-oxidation (e.g. cytochrome P4504A). Here we studied the possibility that hypolipidemic effects of silymarin may be mediated by PPAR?. Rats fed with a high-cholesterol diet with either silymarin or fenofibrate (as a positive control both for PPAR? expression as well as for lipid determination) were used. The effects of silymarin on expression of PPAR? both at the mRNA (including selected target genes) as well as the protein level were determined. In parallel, the levels of cholesterol and triacylglycerols were determined. Our results confirmed the hypolipidemic effects of silymarin and demonstrated that
Název v anglickém jazyce
Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha
Popis výsledku anglicky
Silymarin is widely used in supportive therapy of liver diseases. It has been shown lately that silymarin has beneficial effects on some risk factors of atherosclerosis owing to its hypolipidemic properties. PPAR? plays a key role in lipid metabolism andhomeostasis as its target genes are involved in catabolism of fatty acids by ?-oxidation (e.g. acyl-CoA oxidase) and by ?-oxidation (e.g. cytochrome P4504A). Here we studied the possibility that hypolipidemic effects of silymarin may be mediated by PPAR?. Rats fed with a high-cholesterol diet with either silymarin or fenofibrate (as a positive control both for PPAR? expression as well as for lipid determination) were used. The effects of silymarin on expression of PPAR? both at the mRNA (including selected target genes) as well as the protein level were determined. In parallel, the levels of cholesterol and triacylglycerols were determined. Our results confirmed the hypolipidemic effects of silymarin and demonstrated that
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FR - Farmakologie a lékárnická chemie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/1P05OC065" target="_blank" >1P05OC065: Pleiotropní účinky hypolipidemik</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)
Ostatní
Rok uplatnění
2007
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Xenobiotica
ISSN
0049-8254
e-ISSN
—
Svazek periodika
37
Číslo periodika v rámci svazku
7
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
11
Strana od-do
725-735
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—